Biotechnology Companies By Three Year Return
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Three Year Return
| Three Year Return | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | ICU | LMF Acquisition Opportunities | 0.07 | 5.87 | 0.41 | ||
| 2 | NAMSW | NewAmsterdam Pharma | (0.03) | 5.65 | (0.18) | ||
| 3 | ADMA | ADMA Biologics | 0.06 | 3.32 | 0.21 | ||
| 4 | VKTX | Viking Therapeutics | (0.14) | 4.85 | (0.70) | ||
| 5 | SMMT | Summit Therapeutics PLC | 0.04 | 5.40 | 0.21 | ||
| 6 | NUVL | Nuvalent | (0.05) | 2.63 | (0.14) | ||
| 7 | BLTE | Belite Bio ADR | 0.03 | 2.77 | 0.10 | ||
| 8 | ARDX | Ardelyx | 0.04 | 4.54 | 0.17 | ||
| 9 | ACLX | Arcellx | (0.05) | 3.05 | (0.15) | ||
| 10 | DRUG | Bright Minds Biosciences | (0.01) | 5.09 | (0.07) | ||
| 11 | RYTM | Rhythm Pharmaceuticals | (0.01) | 2.62 | (0.03) | ||
| 12 | TGTX | TG Therapeutics | 0.10 | 3.97 | 0.41 | ||
| 13 | MLTX | MoonLake Immunotherapeutics | (0.19) | 2.84 | (0.53) | ||
| 14 | BHVN | Biohaven Pharmaceutical Holding | (0.08) | 3.90 | (0.30) | ||
| 15 | NTRA | Natera Inc | (0.02) | 2.78 | (0.07) | ||
| 16 | SPRY | Silverback Therapeutics | 0.07 | 4.67 | 0.30 | ||
| 17 | IRON | Disc Medicine | (0.16) | 2.15 | (0.34) | ||
| 18 | INSM | Insmed Inc | 0.07 | 2.23 | 0.16 | ||
| 19 | MDGL | Madrigal Pharmaceuticals | 0.04 | 4.29 | 0.18 | ||
| 20 | BBIO | BridgeBio Pharma | 0.12 | 3.97 | 0.47 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance. Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.